Press "Enter" to skip to content

Patent delisted for Boehringer Ingelheim drug JENTADUETO

1
Copyright © DrugPatentWatch. Originally published at Patent delisted for Boehringer Ingelheim drug JENTADUETO

Annual Drug Patent Expirations for JENTADUETO
Jentadueto is a drug marketed by Boehringer Ingelheim and is included in two NDAs. It is available from one supplier. There are twelve patents protecting this drug and two Paragraph IV challenges.

JENTADUETO drug price trends.

Drug patent litigation for JENTADUETO.

This drug has three hundred and two patent family members in forty-five countries.

The generic ingredient in JENTADUETO is linagliptin; metformin hydrochloride. One supplier is listed for this compound. Additional details are available on the linagliptin; metformin hydrochloride profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

Get the Daily Briefing or Try a trial

Copyright © DrugPatentWatch. Originally published at Patent delisted for Boehringer Ingelheim drug JENTADUETO
Get the DrugPatentWatch Daily Briefing

✓ Patent Expirations and Generic Entry

✓ Insightful Articles & Case Studies

✓ Patent Litigation & Challenges

✓ 505(b)(2) & Biosimilars

✓ Industry Trends

DrugPatentWatch - Make Better Decisions